Back to top
more

Amarin (AMRN)

(Delayed Data from NSDQ)

$16.03 USD

16.03
87,086

+0.26 (1.65%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $15.97 -0.06 (-0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications

by Zacks Equity Research

Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.

Zacks Equity Research

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

by Zacks Equity Research

Candel stock rises as FDA grants RMAT tag to CAN-2409 after phase III success in prostate cancer. BLA submission is planned at the end of 2026.

Zacks Equity Research

Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how GSK (GSK) and Amarin (AMRN) have performed compared to their sector so far this year.

Zacks Equity Research

RCKT Stock Tanks on Patient Death in Danon Disease Study

by Zacks Equity Research

Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts a clinical hold on the study.

Zacks Equity Research

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

by Zacks Equity Research

TEVA starts IND-enabling studies for BD9, a dual-targeting multibody for asthma and eczema. Shares rise on the news.

Zacks Equity Research

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

by Zacks Equity Research

Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.

Zacks Equity Research

AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer

by Zacks Equity Research

AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.

Zacks Equity Research

GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma

by Zacks Equity Research

GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.

Zacks Equity Research

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

by Zacks Equity Research

SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.

Zacks Equity Research

Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases

by Zacks Equity Research

BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.